Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Lab, Consulting), Therapeutic Area (Oncology, Infectious Disease, Neurology, Immunology, Hematology, Vaccines), End User - Global Forecast (2022 - 2027)
[427 Pages Report] The global CRO services market is projected to reach USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0% during the forecast period. Growth in the contract research organization services market can mainly be attributed to the increasing investment in pharmaceutical R&D, rising number of clinical trials, high cost of in-house drug development (encouraging pharma-biotech companies to opt for outsourcing. Growth in the drugs and biologics market despite the COVID-19 pandemic, the increasing demand for specialized testing services among end users, and the need for novel clinical trial designs for complex cell and gene therapies are also expected to offer a wide range of growth opportunities to players operating in this market.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 impact on the CRO Services Market
COVID-19 is an infectious disease caused by the recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 quickly moved from being a regional crisis to a global pandemic. The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the World Health Organization (WHO), there were 435,626,514 confirmed cases of COVID-19, including 5,952,215 deaths, as of March 1, 2022. The highest number of deaths was in the Americas, followed by Europe and Southeast Asia.
With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies have scaled up R&D and manufacturing efforts to develop and distribute test kits, vaccines, and drugs against the SARS-CoV-2 virus. To expedite the R&D process, many pharmaceutical and biotechnology companies teamed up with CROs through long-term agreements, partnerships, and collaborations across the globe. CROs have also developed dedicated services for COVID-19 research. In 2020, a number of new service launches and agreements, partnerships, and collaborations with different pharmaceutical companies and academic institutes for the research & development of COVID-19 vaccines, drugs, and diagnostics were recorded across the globe. Investments have also been made to expand manufacturing facilities. Thus, the COVID-19 outbreak has been a catalyst for outsourcing drug development processes and has positively impacted every aspect of the pharmaceutical contract research industry.
Global Contract Research Organization (CROs) Services Market Dynamics
DRIVER:Increasing investment in pharmaceutical R&D
Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in the development of novel drugs and devices. The pharmaceutical industry, in particular, is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that the top pharmaceutical companies are increasing their R&D efficiencies through heavy investments in R&D and through collaborative R&D efforts. According to the EvaluatePharma report, the global pharmaceutical R&D spending was valued at USD 137 billion in 2012; this increased to USD 212 billion in 2021 and is projected to reach USD 254 billion by 2026. As per the report, R&D spending is observed to be growing steadily at a CAGR of 4.2% from 2020 to 2026. This is expected to boost the outsourcing of research services by pharmaceutical companies, biotechnology companies, as well as research and academic organizations.
OPPORTUNITY:Growth in the drugs and biologics market despite the COVID-19 pandemic
Despite the ongoing COVID-19 pandemic, 2020 has been the second-best year for the pharmaceutical industry in terms of the number of drugs approved by the US FDA. This year witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 comprised 40 new chemical entities and 13 biologics. The approved biologics included 10 monoclonal antibodies, 2 antibody-drug conjugates, 3 peptides, and 2 oligonucleotides. The FDA has authorized 160 drugs in the last three years (2018–2020), compared to the approval of only 21 drugs in 2010. This growth in the number of approved products worldwide is attributed to the rising investments by biopharmaceutical companies to develop biologics and biosimilars. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical product sales in 2022.
CHALLENGE: Shortage of skilled professionals for clinical trials
The global pharmaceutical, biotechnology, and medical device R&D outsourcing industry is constantly evolving. Highly skilled professionals are required to keep pace with the continuing changes in pharmaceutical and medical device R&D technologies and methodologies, provide quality services, and comply with good laboratory practices. CROs face challenges in attracting and retaining highly skilled professionals as they compete with pharmaceutical, biotechnology, and medical device companies as well as academic and research institutions for qualified and experienced scientists. To compete effectively, companies have to offer higher compensations and other benefits; this may affect the finances and results of operations of players, especially small-scale analytical testing providers. This shortage of skilled professionals may hamper the adoption of new technologies and methodologies and inhibit the growth of the CRO services market in the coming years.
According to the Association of Clinical Research Organizations (ACRO), the greatest shortage has been observed for the clinical trial associate (CTA) and clinical research associate (CRA) roles. This crisis has been growing for the last 10 years, with neither pharma companies nor CROs providing enough skills training for graduates to meet the industry’s research needs.
The clinical research services subsegment of the type segment dominated the Contract Research Organization (CROs) Services Market in 2021
Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.
To know about the assumptions considered for the study, download the pdf brochure
North America was the largest regional market for Contract Research Organization (CROs) Services Market in 2021.
North America accounted for the largest share of the global CRO services market in 2021. North America’s dominance in this market is mainly attributed to the rapid growth in the biosimilars and biologics markets, increasing focus on outsourcing among pharmaceutical and biopharmaceutical companies, and the increasing number of clinical trial activities in the region.
Key Market Players
Key players in the global CRO services Market include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (a part of Thermo Fisher Scientific, Inc., ICON plc (Ireland), Charles River Laboratories International, Inc. (US), WuXiAppTec Co., Ltd. (China), Syneos Health Inc. (US), Parexel International Corporation (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2021–2027 |
|
Base year considered |
2021 |
|
Forecast period |
2022–2027 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Type, Therapeutic area, End user and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA) |
|
Companies covered |
IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories International, Inc. (US), WuXi AppTec Co., Ltd. (China), Syneos Health Inc. (US), Parexel International Corporation (US), PPD, Inc. (a part of Thermo Fisher Scientific, Inc.), Pharmaron Beijing Co., Ltd. (China), Clinipace Inc. (US), ICON plc (Ireland), Medpace Holdings Inc. (US), SGS SA (Switzerland), Frontage Holdings Corporation (US), PSI CRO AG (Switzerland), BioAgile Therapeutics Pvt. Ltd. (India), Firma Clinical Research, LLC (US), AccuLab Life Sciences (US), Novotech Health Holdings (Australia), Geneticist Inc. (US), Linical Americas (US), Celerion (US), Azelix LLC (US), Clinical Trial Service BV (Netherlands), Pepgra Healthcare Pvt. Ltd. (UK), Axcent Advanced Analytics, Inc. (US), and Dove Quality Solutions Limited (UK) |
This report categorizes the CRO services market into the following segments and subsegments:
CRO Services Market, by Type
- Clinical Research Services
- Early phase development Services
- Laboratory Services
- Consulting Services
- Data Managenment Services
CRO Services Market, by Clinical Research Services
- Phase III
- Phase II
- Phase I
- Phase IV
CRO Services Market, by Early phase development services
- Chemistry, Manufacturing and Controls Services
- Preclinical Services
- Pharmacokinetics/ Pharmacodynamics Services
- Toxicology Testing Services
- Other Preclinical Services
- Discovery Studies
CRO Services Market, by Laboratory services
- Analytical Testing Services
- Physical Characterization Services
- Raw Material Testing Services
- Batch Release Testing Services
- Stability Testing Services
- Other Analytical Testing Services
- Bioanalytical Testing Services
CRO Services Market, by Therapeutic Area
- Oncology
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Other Cancer
- Infectious Diseases
- CVS Disorders
- Neurology
- Vaccines
- Metabolic Disorders/Endocrinology
- Immunological Disorders
- Psychiatry
- Respiratory Disorders
- Dermatology
- Ophthalmology
- Gastrointestinal Diseases
- Genitourinary & Women’s Health
- Hematology
- Other Therapeutic Areas
CRO Services Market, by End user
- Pharmaceutical & Biopharmaceutical Companies
- Medical Device Companies
- Academic Institutes
CRO Services Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- RoLATAM
- Middle East and Africa (MEA)
Recent Developments
- In December 2021, Laboratory Corporation of America Holdings (US) acquired Toxikon Corporation (US) to collaborate with pharmaceutical and biotechnology clients in the Boston, Massachusetts, area and strengthen its non-clinical development portfolio.
- InJanuary 2021, IQVIA Inc. (US) launched the Clinical Data Analytics Suite (CDAS), a new SaaS-based clinical data analytics platform that combines structured and unstructured data from clinical trials into a single standardized setting for easier access and use, produces scalable repositories, and drives predictive analytics.
Frequently Asked Questions (FAQ):
What is the impact of COVID-19 on theglobal CRO services market?
COVID-19 pandemic has prompted key pharmaceutical and biotechnology companies have scaled up R&D efforts to develop vaccines and drugs against the virus. Vaccine-related research activities in pharmaceutical & biotechnology companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. To expedite the R&D process, many pharmaceutical and biotechnology companies teamed up with CROs through long-term agreements, partnerships, and collaborations across the globe. CROs have also developed dedicated services for COVID-19 research. In 2020, a number of new service launches and agreements, partnerships, and collaborations with different pharmaceutical companies and academic institutes for the research & development of COVID-19 vaccines, drugs, and diagnostics were recorded across the globe. Investments have also been made to expand manufacturing facilities. Thus, the COVID-19 outbreak has been a catalyst for outsourcing drug development processes and has positively impacted every aspect of the pharmaceutical contract research industry.
Who are the key players in theCRO servicesmarket?
Key players in the CRO services market include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (a part of Thermo Fisher Scientific, Inc.), ICON plc (Ireland), Charles River Laboratories International, Inc. (US), WuXiAppTec Co., Ltd. (China), Syneos Health Inc. (US), Parexel International Corporation (US).
Which service segment dominates theCRO services market?
In 2021, the clinical research servicessegment dominated the CRO servicesmarket.The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.
Which therapeutic areasegment of the CRO servicesmarket is expected to witness the highest growth?
Oncology is the largest segment in the CRO services market. Growth in this segment is attributed to the high incidence of cancer, a strong pipeline of drugs in late-stage development, and the large number of cancer-related clinical trials.
What is the market size forthe CROservicesmarket?
The global CROs services market is estimated to grow from USD 68.3 billion in 2022 to reach USD 115.1 billion by 2027, at a CAGR of 11.0% during the forecast period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 55)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 CRO SERVICES MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 61)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION—BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2022–2027
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 72)
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022 VS. 2027 (USD MILLION)
FIGURE 14 CRO SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET
4 PREMIUM INSIGHTS (Page No. - 76)
4.1 CRO SERVICES MARKET OVERVIEW
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY SERVICE & COUNTRY (2021)
FIGURE 17 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN CRO SERVICES MARKET IN 2021
4.3 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2027
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2021
FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CRO SERVICES MARKET FROM 2022 TO 2027
5 MARKET OVERVIEW (Page No. - 80)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing investment in pharmaceutical R&D
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021
5.2.1.2 Increasing number of clinical trial
FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)
5.2.1.3 High cost of in-house drug development
FIGURE 25 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
5.2.1.4 Rising prevalence of orphan and rare diseases
5.2.2 OPPORTUNITIES
5.2.2.1 Growth in the drugs and biologics market despite the COVID-19 pandemic
FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY THE US FDA (2011–2021)
TABLE 2 LIST OF BIOLOGICS APPROVED BY THE US FDA (2021)
5.2.2.2 Rising demand for specialized testing services among end users
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals for clinical trials
5.2.3.2 Requirement for unique analytical testing approaches for innovative formulations
5.2.4 MARKET TRENDS
5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery
5.2.4.2 Increased outsourcing to emerging Asian economies
5.2.4.3 CRO industry consolidation
TABLE 3 LIST OF ACQUISITIONS
5.2.4.4 Integrated end-to-end R&D service solutions
5.3 RANGES/SCENARIOS
FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CRO SERVICES MARKET
5.4 IMPACT OF COVID-19 OUTBREAK ON THE CRO SERVICES MARKET
FIGURE 28 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 29 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS
5.6 PRICING ANALYSIS
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020)
5.7 VALUE CHAIN ANALYSIS
FIGURE 30 VALUE CHAIN ANALYSIS OF THE CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE
5.8 ECOSYSTEM ANALYSIS
FIGURE 31 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET
TABLE 5 SUPPLY CHAIN ECOSYSTEM
5.9 TECHNOLOGY ANALYSIS
5.10 CASE STUDIES
5.10.1 COVANCE FSPX DATA ANALYSIS WAS USED TO DETERMINE THE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIALS
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR
5.11 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 6 CRO SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.12 REGULATORY ANALYSIS
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 11 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 DEGREE OF COMPETITION
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF CRO SERVICES
5.14.2 BUYING CRITERIA FOR CRO SERVICES
FIGURE 33 KEY BUYING CRITERIA FOR END USERS
6 CRO SERVICES MARKET, BY TYPE (Page No. - 110)
6.1 INTRODUCTION
TABLE 12 CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 CLINICAL RESEARCH SERVICES
TABLE 13 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF MARCH 2022, BY LOCATION
TABLE 14 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
FIGURE 34 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2020 VS. 2021
TABLE 15 CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 PHASE III CLINICAL RESEARCH SERVICES
6.2.1.1 Rising cost of Phase III trials and high number of patients recruited in these trials to drive the demand for cost-effective CRO services
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY
TABLE 22 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 23 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 PHASE II CLINICAL RESEARCH SERVICES
6.2.2.1 Long duration of Phase II studies provides growth opportunities for CROs
TABLE 27 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
TABLE 28 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 29 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 PHASE I CLINICAL RESEARCH SERVICES
6.2.3.1 Robust pipeline of pharmaceutical companies driving the growth of this market segment
TABLE 33 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES
TABLE 34 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES
6.2.4.1 Increasing number of CROs are providing post-marketing surveillance
TABLE 39 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
TABLE 40 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 EARLY-PHASE DEVELOPMENT SERVICES
FIGURE 35 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2021)
TABLE 45 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
TABLE 46 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 48 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 51 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.1 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES
6.3.1.1 CMC services are widely used to check the quality standards of drugs
TABLE 52 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 ASIA PACIFIC: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 LATIN AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 PRECLINICAL SERVICES
TABLE 57 PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 PRECLINICAL SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2.1 Pharmacokinetics/pharmacodynamics services
6.3.2.1.1 Importance of studies to determine the pharmacokinetic behavior of drug candidates is increasing
TABLE 63 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2.2 Toxicology testing services
6.3.2.2.1 Demand for toxicology testing is increasing to prevent late-stage failures
TABLE 68 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 72 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2.3 Other preclinical services
TABLE 73 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3 DISCOVERY STUDIES
6.3.3.1 Rising importance of CRO services for target identification and validation to promote segment growth
TABLE 78 DISCOVERY STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 79 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 LABORATORY SERVICES
TABLE 83 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 84 LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 LABORATORY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 86 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 89 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.1 ANALYTICAL TESTING SERVICES
TABLE 90 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 92 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 93 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.1.1 Physical characterization services
6.4.1.1.1 Demand for physical characterization is increasing to reduce the risk of product failure
TABLE 96 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 99 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 100 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.1.2 Raw material testing services
6.4.1.2.1 Demand for raw material testing services is increasing to ensure the quality and purity of raw materials
TABLE 101 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 105 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.1.3 Batch release testing services
6.4.1.3.1 Comprehensive portfolio of batch release testing services offered by CROs to propel segment growth
TABLE 106 BATCH RELEASE TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 108 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 110 LATIN AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.1.4 Stability testing services
6.4.1.4.1 Stability testing is used to ensure the long-term quality, safety, and efficacy of pharmaceutical products
TABLE 111 STABILITY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 112 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 113 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 114 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 115 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.1.5 Other analytical testing services
TABLE 116 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 117 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 118 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 119 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 120 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.2 BIOANALYTICAL TESTING SERVICES
6.4.2.1 Demand for bioanalytical testing has increased due to the growing use of macromolecules and biosimilars
TABLE 121 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 122 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 123 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 124 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 CONSULTING SERVICES
6.5.1 ADOPTION OF CONSULTING SERVICES IS INCREASING FOR QUALITY ASSURANCE PURPOSES
TABLE 126 CONSULTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 127 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 129 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 130 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 DATA MANAGEMENT SERVICES
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD
TABLE 131 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 132 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 133 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 134 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 136 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 166)
7.1 INTRODUCTION
TABLE 137 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
7.2 ONCOLOGY
FIGURE 36 GLOBAL CANCER INCIDENCE, BY CANCER TYPE (2020)
FIGURE 37 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM 2011 TO 2021 (IN THOUSAND)
TABLE 138 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2021)
TABLE 139 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 141 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 142 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 143 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 144 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 BREAST CANCER
7.2.1.1 Breast cancer is the most prevalent cancer
TABLE 145 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)
TABLE 146 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 147 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 148 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 149 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 LUNG CANCER
7.2.2.1 Drug approvals indicate increasing research against lung cancer
TABLE 150 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)
TABLE 151 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 152 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 153 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 154 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 COLORECTAL CANCER
7.2.3.1 Increasing number of clinical trials on treatments against colorectal cancer to drive segment growth
TABLE 155 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION)
TABLE 156 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 157 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 158 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 159 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 PROSTATE CANCER
7.2.4.1 Increasing research initiatives on prostate cancer to drive segment growth
TABLE 160 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 162 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 164 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.5 OTHER CANCERS
TABLE 165 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 166 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 167 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 168 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 169 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 INFECTIOUS DISEASES
7.3.1 EPIDEMIC OUTBREAKS ARE NECESSITATING INCREASING DRUG DISCOVERY ACTIVITIES
TABLE 170 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 171 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 172 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 173 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 174 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 CARDIOVASCULAR SYSTEM DISORDERS
7.4.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
TABLE 175 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2021)
TABLE 176 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 178 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 180 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 NEUROLOGY
7.5.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH
TABLE 181 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2021)
TABLE 182 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 183 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 184 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 185 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 186 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 VACCINES
7.6.1 INCREASING INVESTMENTS IN VACCINE R&D TO DRIVE SEGMENT GROWTH
TABLE 187 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2020–2027 (USD MILLION)
TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 189 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
7.7 METABOLIC DISORDERS/ENDOCRINOLOGY
7.7.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE SEGMENT GROWTH
FIGURE 38 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
TABLE 192 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 193 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 194 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 195 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 196 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.8 IMMUNOLOGICAL DISORDERS
7.8.1 GROWING DRUGS PIPELINE FOR IMMUNOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH
TABLE 197 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 198 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 199 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 200 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 201 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.9 PSYCHIATRY
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL SEGMENT GROWTH
TABLE 202 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2020–2027 (USD MILLION)
TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 204 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION)
7.10 RESPIRATORY DISORDERS
7.10.1 INCREASING PREVALENCE OF RESPIRATORY DISORDERS TO SUPPORT SEGMENT GROWTH
TABLE 207 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2021)
TABLE 208 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 209 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 210 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 211 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 212 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.11 DERMATOLOGY
7.11.1 INCREASING PREVALENCE OF SKIN DISORDERS TO PROPEL SEGMENT GROWTH
TABLE 213 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2021)
TABLE 214 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 215 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 216 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 217 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 218 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.12 OPHTHALMOLOGY
7.12.1 GROWING NEED FOR OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT GROWTH
TABLE 219 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 220 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 221 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 222 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 223 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.13 GASTROINTESTINAL DISEASES
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO PROPEL SEGMENT GROWTH
TABLE 224 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 226 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.14 GENITOURINARY & WOMEN’S HEALTH
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO DRIVE SEGMENT GROWTH
TABLE 229 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2020–2027 (USD MILLION)
TABLE 230 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 231 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 232 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 233 LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2020–2027 (USD MILLION)
7.15 HEMATOLOGY
7.15.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH
TABLE 234 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 235 NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 236 EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 237 ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 238 LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.16 OTHER THERAPEUTIC AREAS
TABLE 239 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2020–2027 (USD MILLION)
TABLE 240 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 241 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 242 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 243 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION)
7.17 CUSTOMIZATION
7.17.1 CELL & GENE THERAPY
7.17.1.1 Increasing funding for R&D to support segment growth
TABLE 244 CRO SERVICES MARKET FOR CELL & GENE THERAPY, 2020–2027 (USD MILLION)
7.17.2 BIOSIMILARS
7.17.2.1 Patent expiration of biologics to drive segment growth
TABLE 245 CRO SERVICES MARKET FOR BIOSIMILARS, 2020–2027 (USD MILLION)
8 CRO SERVICES MARKET, BY END USER (Page No. - 216)
8.1 INTRODUCTION
TABLE 246 CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
8.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO DRIVE MARKET GROWTH
FIGURE 39 ANNUAL DRUG APPROVALS BY CDER (FDA), 2012–2021
FIGURE 40 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2020
TABLE 247 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 248 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 249 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 250 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 251 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 MEDICAL DEVICE COMPANIES
8.3.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE MARKET GROWTH
FIGURE 41 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2011–2021)
FIGURE 42 R&D EXPENSES OF LEADING MEDICAL DEVICE COMPANIES, 2020 (USD MILLION)
TABLE 252 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 253 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 254 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 255 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 256 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 ACADEMIC INSTITUTES
8.4.1 COLLABORATIONS BETWEEN ACADEMIC INSTITUTES AND CROS TO DRIVE MARKET GROWTH
TABLE 257 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 258 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 259 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 260 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 261 LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
9 CRO SERVICES MARKET, BY REGION (Page No. - 228)
9.1 INTRODUCTION
TABLE 262 CRO SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 43 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
TABLE 263 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 264 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 265 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 266 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 267 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 268 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 270 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 271 NORTH AMERICA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 272 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 US dominates the CRO services market in North America
FIGURE 44 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2020 VS. 2021)
TABLE 273 US: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 274 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 275 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 276 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 277 US: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 280 US: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 281 US: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Increasing number of clinical trials to support market growth
TABLE 282 CANADA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 283 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 284 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 285 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 286 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 287 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 288 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 289 CANADA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 CANADA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3 EUROPE
FIGURE 45 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
TABLE 291 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 292 EUROPE: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 293 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 294 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 295 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 296 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 297 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 298 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 299 EUROPE: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 EUROPE: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany is a favorable location for clinical trials due to government support and flexible labor laws
TABLE 301 GERMANY: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 302 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 303 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 304 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 305 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 306 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 307 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 308 GERMANY: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 309 GERMANY: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth
FIGURE 46 UK: PHARMACEUTICAL R&D EXPENDITURE, 2011–2020 (USD MILLION)
TABLE 310 UK: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 312 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 313 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 314 UK: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 315 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 316 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 317 UK: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 318 UK: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 High number of oncology clinical trials to drive market growth
TABLE 319 FRANCE: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 321 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 322 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 323 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 324 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 325 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 326 FRANCE: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 327 FRANCE: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Low drug approval time and growing number of clinical trials to drive market growth
TABLE 328 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 329 ITALY: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 330 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 331 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 332 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 333 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 334 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 335 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 336 ITALY: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 337 ITALY: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Short study start-up times and rising R&D expenditure to boost market growth
FIGURE 47 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2011–2017 (USD MILLION)
TABLE 338 SPAIN: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 339 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 340 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 341 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 342 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 343 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 344 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 345 SPAIN: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 346 SPAIN: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 347 ROE: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 348 ROE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 349 ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 350 ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 351 ROE: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 352 ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 353 ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 354 ROE: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 355 ROE: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 48 APAC: CRO SERVICES MARKET SNAPSHOT
TABLE 356 APAC: CRO SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 357 APAC: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 358 APAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 359 APAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 360 APAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 361 APAC: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 362 APAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 363 APAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 364 APAC: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 365 APAC: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 China dominates the APAC CRO services market
TABLE 366 CHINA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 367 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 368 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 369 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 370 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 371 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 372 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 373 CHINA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 374 CHINA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Strong focus on research to drive market growth
TABLE 375 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2019 VS. 2021
TABLE 376 JAPAN: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 377 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 378 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 379 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 380 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 381 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 382 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 383 JAPAN: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 384 JAPAN: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growing pharmaceutical industry to drive market growth
TABLE 385 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2019 VS. 2021
TABLE 386 INDIA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 387 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 388 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 389 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 390 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 391 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 392 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 393 INDIA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 394 INDIA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 Australia is considered a favorable location for drug discovery due to a large number of research institutes
TABLE 395 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 396 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 397 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 398 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 399 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 400 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 401 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 402 AUSTRALIA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 403 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.5 SOUTH KOREA
9.4.5.1 Government initiatives and growing R&D activities for drug development to drive market growth
TABLE 404 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 405 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 406 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 407 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 408 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 409 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 410 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 411 SOUTH KOREA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 412 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.6 REST OF ASIA PACIFIC
TABLE 413 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2019 VS. 2021
TABLE 414 ROAPAC: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 415 ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 416 ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 417 ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 418 ROAPAC: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 419 ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 420 ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 421 ROAPAC: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 422 ROAPAC: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5 LATIN AMERICA
TABLE 423 LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 424 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 425 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 426 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 427 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 428 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 429 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 430 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 431 LATIN AMERICA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 432 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Gradual growth in research to help market growth
TABLE 433 BRAZIL: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 434 BRAZIL: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 435 BRAZIL: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 436 BRAZIL: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 437 BRAZIL: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 438 BRAZIL: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 439 BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 440 BRAZIL: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 441 BRAZIL: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5.2 REST OF LATIN AMERICA
TABLE 442 ROLA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 443 ROLA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 444 ROLA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 445 ROLA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 446 ROLA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 447 ROLA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 448 ROLA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 449 ROLA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 450 ROLA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
TABLE 451 MEA: CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 452 MEA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 453 MEA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 454 MEA: PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 455 MEA: LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 456 MEA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 457 MEA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 458 MEA: ONCOLOGY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 459 MEA: CRO SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 317)
10.1 INTRODUCTION
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 49 CRO SERVICES MARKET: STRATEGIES ADOPTED
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 50 REVENUE ANALYSIS OF KEY COMPANIES OVER THE LAST THREE YEARS (2019–2021)
10.4 MARKET SHARE ANALYSIS
FIGURE 51 CRO SERVICES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
TABLE 460 CRO SERVICES MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT
FIGURE 52 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX, 2021
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPETITIVE BENCHMARKING OF THE TOP 26 PLAYERS
10.6.1 OVERALL FOOTPRINT OF COMPANIES (26 COMPANIES)
FIGURE 53 OVERALL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CRO SERVICES MARKET
10.6.2 INDUSTRY FOOTPRINT OF COMPANIES (26 COMPANIES)
TABLE 461 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CRO SERVICES MARKET
10.6.3 SERVICE FOOTPRINT OF COMPANIES (26 COMPANIES)
TABLE 462 SERVICE FOOTPRINT ANALYSIS OF THE KEY PLAYERS IN THE CRO SERVICES MARKET
10.6.4 REGIONAL FOOTPRINT OF COMPANIES (26 COMPANIES)
TABLE 463 REGIONAL FOOTPRINT ANALYSIS OF THE KEY PLAYERS IN THE CRO SERVICES MARKET
10.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES
FIGURE 54 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
10.7.1 PROGRESSIVE COMPANIES
10.7.2 STARTING BLOCKS
10.7.3 RESPONSIVE COMPANIES
10.7.4 DYNAMIC COMPANIES
10.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 464 CRO SERVICES MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 465 CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
10.9 COMPETITIVE SCENARIO AND TRENDS
10.9.1 SERVICES LAUNCHES
TABLE 466 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2017–JANUARY 2022
10.9.2 DEALS
TABLE 467 CRO SERVICES MARKET: DEALS, JANUARY 2017–JANUARY 2022
10.9.3 EXPANSIONS
TABLE 468 CRO SERVICES MARKET: EXPANSIONS, JANUARY 2017–JANUARY 2022
11 COMPANY PROFILES (Page No. - 335)
11.1 KEY COMPANIES
(Business overview, Services offered, Recent developments, MnM view, Key strengths/right to win, Strategic choices, and Weaknesses and competitive threats)*
11.1.1 IQVIA INC.
TABLE 469 IQVIA INC.: BUSINESS OVERVIEW
FIGURE 55 IQVIA INC.: COMPANY SNAPSHOT (2021)
11.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
TABLE 470 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
FIGURE 56 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
11.1.3 PPD INC. (A PART OF THERMO FISHER SCIENTIFIC, INC.)
TABLE 471 PPD INC.: BUSINESS OVERVIEW
FIGURE 57 PPD INC: COMPANY SNAPSHOT (2021)
11.1.4 SYNEOS HEALTH INC.
TABLE 472 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
FIGURE 58 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021)
11.1.5 WUXI APPTEC CO., LTD.
TABLE 473 WUXI APPTEC CO., LTD.: BUSINESS OVERVIEW
FIGURE 59 WUXI APPTEC CO., LTD.: COMPANY SNAPSHOT (2021)
11.1.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 474 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
FIGURE 60 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
11.1.7 PAREXEL INTERNATIONAL CORPORATION
TABLE 475 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
11.1.8 PHARMARON BEIJING CO., LTD.
TABLE 476 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
FIGURE 61 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2020)
11.1.9 ICON PLC
TABLE 477 ICON PLC: BUSINESS OVERVIEW
FIGURE 62 ICON PLC: COMPANY SNAPSHOT (2021)
11.1.10 MEDPACE HOLDINGS, INC.
TABLE 478 MEDPACE HOLDINGS, INC.: BUSINESS OVERVIEW
FIGURE 63 MEDPACE HOLDINGS, INC: COMPANY SNAPSHOT (2021)
11.1.11 SGS SA
TABLE 479 SGS SA: BUSINESS OVERVIEW
FIGURE 64 SGS SA: COMPANY SNAPSHOT (2021)
11.1.12 FRONTAGE HOLDINGS CORPORATION
TABLE 480 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 65 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
11.1.13 PSI CRO AG
TABLE 481 PSI CRO AG: BUSINESS OVERVIEW
11.1.14 BIOAGILE THERAPEUTICS PVT. LTD.
TABLE 482 BIOAGILE THERAPEUTICS PVT. LTD.: BUSINESS OVERVIEW
11.1.15 FIRMA CLINICAL RESEARCH, LLC
TABLE 483 FIRMA CLINICAL RESEARCH, LLC: BUSINESS OVERVIEW
11.1.16 ACCULAB LIFE SCIENCES
TABLE 484 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW
11.1.17 NOVOTECH HEALTH HOLDINGS
TABLE 485 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW
11.1.18 GENETICIST INC.
TABLE 486 GENETICIST INC.: BUSINESS OVERVIEW
11.1.19 LINICAL AMERICAS
TABLE 487 LINICAL AMERICAS: BUSINESS OVERVIEW
11.1.20 CELERION
TABLE 488 CELERION: BUSINESS OVERVIEW
11.1.21 CLINIPACE INC.
TABLE 489 CLINIPACE INC.: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 AZELIX LLC
11.2.2 CLINICAL TRIAL SERVICE BV
11.2.3 PEPGRA HEALTHCARE PVT. LTD.
11.2.4 AXCENT ADVANCED ANALYTICS (A3), INC.
11.2.5 DOVE QUALITY SOLUTIONS LIMITED
*Details on Business overview, Services offered, Recent developments, MnM view, Key strengths/right to win, Strategic choices, and Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 420)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global Contract Research Organization (CROs) Services Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources, such as the Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICRO), Clinical and Contract Research Association (CCRA), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global CRO services market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global CRO services market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CRO services market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive primary and secondary research.
- The revenues generated from the CRO services business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Report Objectives
- To define, describe, and forecast the contract research organization (CRO) services market based on type, therapeutic area, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and challenges) along with the current trends
- To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the revenue of market segments with respect to five major regions, namely,
- North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments in the CRO services market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
Growth opportunities and latent adjacency in Contract Research Organization (CROs) Services Market
Which region will lead the global contract research organization services market?
Who are the major players operating in the contract research organization services market?
Which are the driving factors of the contract research organization services market?